HPV Genotypes in High Grade Cervical Lesions and Invasive Cervical Carcinoma as Detected by Two Commercial DNA Assays, North Carolina, 2001–2006 by Hariri, Susan et al.
HPV Genotypes in High Grade Cervical Lesions and
Invasive Cervical Carcinoma as Detected by Two
Commercial DNA Assays, North Carolina, 2001–2006
Susan Hariri
1*, Martin Steinau
2, Allen Rinas
3, Julia W. Gargano
2,4, Christina Ludema
3, Elizabeth R. Unger
2,
Alicia L. Carter
5, Kathy L. Grant
6, Melanie Bamberg
7, James E. McDermott
7, Lauri E. Markowitz
1,
Noel T. Brewer
3, Jennifer S. Smith
3
1Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United
States of America, 2Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control
and Prevention, Atlanta, Georgia, United States of America, 3Gillings School of Global Public Health and Lineberger Comprehensive Cancer Center, University of North
Carolina, Chapel Hill, North Carolina, United States of America, 4Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
of America, 5Laboratory Corporation of AmericaH Holdings, Burlington, North Carolina, United States of America, 6Duke University Health System, Durham, North
Carolina, United States of America, 7Carolinas Medical Center, Charlotte, North Carolina, United States of America
Abstract
Background: HPV typing using formalin fixed paraffin embedded (FFPE) cervical tissue is used to evaluate HPV vaccine
impact, but DNA yield and quality in FFPE specimens can negatively affect test results. This study aimed to evaluate 2
commercial assays for HPV detection and typing using FFPE cervical specimens.
Methods: Four large North Carolina pathology laboratories provided FFPE specimens from 299 women ages18 and older
diagnosed with cervical disease from 2001 to 2006. For each woman, one diagnostic block was selected and unstained serial
sections were prepared for DNA typing. Extracts from samples with residual lesion were used to detect and type HPV using
parallel and serial testing algorithms with the Linear Array and LiPA HPV genotyping assays.
Findings: LA and LiPA concordance was 0.61 for detecting any high-risk (HR) and 0.20 for detecting any low-risk (LR) types,
with significant differences in marginal proportions for HPV16, 51, 52, and any HR types. Discordant results were most often
LiPA-positive, LA-negative. The parallel algorithm yielded the highest prevalence of any HPV type (95.7%). HR type
prevalence was similar using parallel (93.1%) and serial (92.1%) approaches. HPV16, 33, and 52 prevalence was slightly lower
using the serial algorithm, but the median number of HR types per woman (1) did not differ by algorithm. Using the serial
algorithm, HPV DNA was detected in .85% of invasive and .95% of pre-invasive lesions. The most common type was
HPV16, followed by 52, 18, 31, 33, and 35; HPV16/18 was detected in 56.5% of specimens. Multiple HPV types were more
common in lower grade lesions.
Conclusions: We developed an efficient algorithm for testing and reporting results of two commercial assays for HPV
detection and typing in FFPE specimens, and describe HPV type distribution in pre-invasive and invasive cervical lesions in a
state-based sample prior to HPV vaccine introduction.
Citation: Hariri S, Steinau M, Rinas A, Gargano JW, Ludema C, et al. (2012) HPV Genotypes in High Grade Cervical Lesions and Invasive Cervical Carcinoma as
Detected by Two Commercial DNA Assays, North Carolina, 2001–2006. PLoS ONE 7(3): e34044. doi:10.1371/journal.pone.0034044
Editor: Ana Paula Arez, Instituto de Higiene e Medicina Tropical, Portugal
Received January 3, 2012; Accepted February 24, 2012; Published March 29, 2012
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: Funding was provided by the Centers for Disease Control and Prevention, grant #S3715-25/2. The funders collaborated on study design, analysis,
decision to publish, and preparation of the manuscript.
Competing Interests: Co-author Alicia Carter is an Associate Vice President, the Atlantic Division Medical Director, and an Anatomic Pathology Discipline
Director at LabCorp. She states that she does not have any declarations relating to SH’s employment, consultancy, patents, or any other products that would alter
the adherence to all the PLoS ONE policies on sharing data and materials. All other authors have declared that no competing interests exist that may alter their
adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: shariri@cdc.gov
Introduction
Reducing the burden of cervical cancer is the key benefit of
HPV prophylactic vaccines. In the U.S., state-based cancer
registries will serve as the basis for evaluating vaccine impact on
invasive HPV-associated cancers, including cervical cancers, as
these lesions are reportable [1]. However, given the long time
period between type-specific HPV infection and development of
invasive cancer, this impact will not be detectable for decades [2].
Pre-invasive cervical lesions detected through screening can serve
as intermediate measures of vaccine impact in settings where
routine cervical cancer screening and systematic reporting systems
are established [3]. Although not all state cancer registries
currently require reporting of preinvasive cervical lesions (cervical
intraepithelial neoplasia grades 2 and 3 [CIN 2,3], adenocar-
inoma-in-situ [AIS]), sentinel systems have been established across
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34044the U.S. to monitor the population impact of HPV vaccine on
these clinical endpoints [4].
In addition to monitoring pre-invasive and invasive cervical
endpoints, determining HPV type-distribution in these lesions is
important to ensure vaccine-associated types are decreasing as
vaccination coverage increases. Linking state cancer registries and
sentinel systems to diagnostic pathology laboratories makes it
possible to retrieve representative tissue for HPV detection and
typing. Standardized laboratory methods adapted for optimal HPV
testing in these archived formalin-fixed paraffin-embedded (FFPE)
tissues are needed to assure that time trends in data reflect reliable
measurement [5]. It is recognized that the yield and quality of DNA
from FFPE tissue is limited, and even with optimal methods of
extraction, the size limit for reliable amplification from FFPE is
around 450 base pairs (bp). The PGMY09/11 primers, used in the
Roche Linear Array HPV Genotyping Assay (LA), generate a 450
bp amplicon, raising concerns that this method may not yield
optimal results in FFPE. An alternative is the SPF primer system
used intheInnogeneticsLineProbe Assay(LiPA),whichgeneratesa
65 bpamplicon.Wheeleretal.[6]used LAandFFPEsamples, with
re-testing of negative or inadequate samples with a non-commercial
version of LiPA. This is an attractive option, but the impact of using
both assays in this sequential manner on the observed type-
distribution has not been formally investigated.
The objectives of this study were to 1) develop an efficient
algorithm for testing and reporting results of two commercial assays
for HPV detection and typing in archived FFPE tissue specimens
(LA and LiPA), and 2) describe HPV type distribution in CIN2/3,
AIS, squamous cell carcinoma (SCC), and adenocarcinoma (ADC)
in a state-based sample prior to HPV vaccine introduction.
Materials and Methods
This study was approved by the University of North Carolina at
Chapel Hill Institutional Review Board. Written consent from the
patients was waived by the ethics board because the data were
obtained and analyzed anonymously.
Study Samples
Four pathology laboratories in North Carolina participated in
this study: Carolinas Medical Center, Duke University Health
System, Laboratory Corporation of AmericaH Holdings, and the
University of North Carolina Health Care. Combined, these
laboratories serve a large majority of the population in North
Carolina and cover a wide geographical distribution within the
state. Each lab searched their pathology database to generate a
completelistofCIN2,CIN3,AIS,andinvasivecervicalcancercases
diagnosed in women ages 18 years and older from January 1, 2001
to June 1, 2006. After stratifying cases by diagnosis (i.e., CIN2,
CIN3/AIS, and invasive cervical cancer), a random sample of 25
cases was selected within each stratum (,300 samples in total). One
block representative of the histology from each of the selected cases
was retrieved for type-specific HPV DNA testing. Demographic
information retrieved from the pathology records that was linked to
the de-identified case number included histologic diagnosis (CIN2,
CIN3, AIS, SCC, ADC, adenosquamous cell carcinoma, and other
invasive cervical cancer), and other data when available, including
age at diagnosis, race, and insurance coverage.
Laboratory Procedures
Histopathology review: Serial sections were cut from each
block using precautions to prevent PCR contamination between
cases, including single-use disposable microtome blades, cleaning
the microtome between cases, and direct transfer of sections for
PCR from microtome to sterile tubes using new single-use
applicators (no contact with waterbath). The first and last sections
were stained with Hematoxylin and Eosin (H&E). Intervening
sections were transferred into 2 mL conical screw cap tubes with
tether caps, one 10-micron section or two 5-micron sections per
tube (Simport, Beloeil, Canada). A study pathologist (ERU)
reviewed the H&E stained sections to confirm that histology was
representative of the diagnosis. Samples that did not have
representative material were not processed.
DNA isolation: DNA was extracted and purified by a
modified protocol using the DNeasy kit (Qiagen, Valencia, CA)
as described elsewhere [7]. Briefly, sections were heated for
20 min at 120uC in 180 ml ATL lysis buffer, then incubated with
Proteinase K overnight at 65uC and further purified with spin
columns. DNA was eluted in a final volume of 100 mL and tested
immediately or stored at 220uC. For every batch of 28 samples, a
water blank was processed through all steps of extraction to serve
as a ‘‘contamination control’’.
HPV Genotyping Tests: All DNA extracts were tested with
LA and LiPA HPV typing assays, both based on L1 consensus
PCR and type-specific hybridization. The LA (Roche Diagnostics,
Indianapolis, IN) uses biotinylated PGMY09/11 and b-globin
primer sets and detects 37 individual HPV types (6, 11, 16, 18, 26,
31, 33, 35, 39, 40, 42, 45, 51, XR(52), 53, 54, 55, 56, 58, 59, 61,
62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89, IS39)
along with b-globin as an internal control. The manufacturer’s
protocol was followed with the exceptions of using 10 mL extract in
the 100-mL PCR reaction and automated hybridization and
washing of the reverse line blot with the Beeblot instrument (Bee
Robotics, Caernarfon, UK). Samples positive for the XR(52)
probe on the LA HPV strip that were also positive for HPV33, 35
and 58 were further evaluated to confirm or exclude the presence
of HPV 52 using an HPV 52 quantitative PCR assay with a
threshold of 50 viral copies [8]. Samples negative for both b-globin
and HPV were considered inadequate for evaluation.
LiPA (Innogenetics, Gent, Belgium) uses SPF10 primers and
detects 28 HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 43, 44,
45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69, 70, 71, 73, 74, 81, 82) as
well as a generic probe to detect other HPV types (HPV X) and a
genomic control probe. The PCR and amplicon hybridization to
the HPV genotyping strip (AutoBlot 3000H, MedTec, Buffalo, IL)
followed the manufacturer’s protocols. The manufacturer’s algo-
rithm for interpretation of typing result based on pattern of positive
probes was followed. This algorithm includes reporting unequivocal
detection of types as well as ‘‘possible types’’. The ambiguity results
from certain hybridizationpatterns and affectsonlytypes 39,52, 54,
68, 69, and 71. Samples negative for both the genomic control
probe and HPV were considered inadequate for evaluation.
Statistical Analysis
Concordance between LA and LiPA: For specimens with
adequate LA and LiPA results, we calculated kappa to assess
congruence of the type-specific results and performed McNemar’s
test to identify differences in the marginal frequencies by typing
assay. Because of the large number of comparisons, we used a
threshold of p,.01 to assess significance of the McNemar’s test.
We performed these analyses for each HPV type present in both
tests. We defined HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66, and 68, as high risk (HR) HPV types, HPV 26, 53, 67, 69,
70, 73, 82, 85, and IS39 as ‘‘Possible HR’’, and HPV 6, 11, 32, 40,
42, 43, 44, 54, 55, 61, 62, 64, 71, 72, 74, 81, 83, 84, 87, 89 as low
risk (LR) HPV [9,10]. Concordance evaluations were restricted to
unequivocal positive LiPA results and repeated with ‘‘possible
type’’ LiPA results interpreted as positive.
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results. These were 1) parallel algorithm, in which results of both tests
were considered for all samples (positive result=positive for either
test) and 2) serial algorithm, in which the LiPA assay results were
only considered for those samples that were inadequate or
negative for any HPV type by LA. We calculated the type-specific
prevalence and overall HR or LR prevalence by each algorithm.
We also calculated the mean and median number of HPV types
detected per woman for each algorithm.
HPV Type Distribution: We examined HPV type distribu-
tion stratified by grade of cervical diagnosis. For evaluating
vaccine-type HPV prevalence, we examined cases positive for
HPV16 or 18 within each diagnosis stratum. We used Pearson’s x
2
test for independence to evaluate bivariate associations between
vaccine-type HPV prevalence and race, stratified by diagnosis
category. The Cochran-Armitage test was used to examine age
trends of HPV 16/18 positivity within each diagnosis grade for 3
age groups (,30, 30–39, .=40). We examined bivariate
associations between single and multiple infections and 1) disease
grade, and 2) age group using Pearson’s x
2 test. Two-sided
statistical tests were considered significant at the alpha level of
0.05. Data were analyzed using SAS (v 9.1, SAS Institute, Cary,
NC, 2002).
Results
Of 299 specimens submitted, 17 were not processed because the
block did not have diagnostic material (5.7%). Of the 282 samples
processed for HPV testing, 15 (5.3%) were inadequate by LA only, 7
(2.5%) by LiPA, and 4 (1.4%) by both methods (p,.01). One sample
was only tested with LA due to insufficient residual volume for LiPA
assay. The remaining 255 samples with valid results in LA and LiPA
were used for comparison of the methods. When comparing LA to
unequivocal LiPA results for 25 types common to both assays,
individual type concordance ranged from 0.33 to 1.00 (median 0.76)
(Table 1). Concordance for detecting any 14 HR type was 0.61 and
concordance for detecting any LR type was 0.20; concordance was
better when analysis was restricted to the 4 LR types common to
both assays (kappa=0.53 and 0.65, respectively). In all cases,
agreement between LA and LiPA was worse when possibly present
LiPA results were interpreted as positive. Concordance declined the
mostfor types39, 52, and54, to 0.30, 0.31, and0.05,respectively.In
allsubsequent analyses,‘‘possible type’’LiPAresultswereconsidered
negative. McNemar’s test detected statistically significant differences
in marginal proportions for HPV 16, 51, 52, and any HR-HPV.
Discordant results were more often LiPA-positive, LA-negative than
LA-positive, LiPA-negative.
Table 1. Concordance between Linear Array (LA) and LiPA test results for HPV types included in both assays.
HPV TYPE LA+ LiPA+ LA+ LiPA2 LA2 LiPA + LA2 LiPA2 kappa P (McNemar’s)
6 1 1 1 252 0.50 1.00
11 1 0 2 252 0.50 0.16
26 1 0 0 254 1.00 –
40 1 0 0 254 1.00 –
53 1 0 2 252 0.50 0.16
54 0 1 0 254 – –
69 0 1 0 254 – –
70 2 0 0 253 1.00 –
71 0 0 0 255 – –
73 1 3 0 251 0.40 0.08
82 2 0 3 250 0.57 0.08
16 123 3 15 114 0.86 ,.01
18 17 2 2 234 0.89 1.00
31 13 1 6 235 0.77 0.06
33 12 2 5 236 0.76 0.26
35 6 1 2 246 0.79 0.56
39 4 1 2 248 0.72 0.56
45 8 4 1 242 0.75 0.18
51 8 0 11 236 0.57 ,.001
52 16 4 16 219 0.57 ,.01
56 5 1 1 248 0.83 1.00
58 12 2 1 240 0.88 0.56
59 1 4 0 250 0.33 0.05
66 5 0 4 246 0.71 0.05
68 2 0 0 253 1.00 –
Any high risk (HR) 225 0 16 4 0.61 ,.0001
Note. High risk HPV types include 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. Restricted to samples with adequate genotyping results for both methods
(N=255). Kappa was calculated only on samples that were positive on both tests.
doi:10.1371/journal.pone.0034044.t001
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As expected, the parallel algorithm yielded the highest
prevalence of any HPV type (95.7%) as well as HR HPV
(93.1%) (Table 2). Applying the serial algorithm resulted in nearly
the same HR-HPV prevalence as the parallel algorithm (92.1%).
However, the prevalence of a few types appeared somewhat lower
Table 2. Prevalence of HPV high risk and low risk types, depending on algorithm for combining linear array (LA) and LiPA results.
HPV Type Prevalence According to Testing Algorithm
HPV Type Included in LA Included in LiPA Parallel Serial
N% N * % *
6 X X 3 1.1 3 1.1
11 X X 3 1.1 1 0.4
16 X X 146 52.7 139 50.2
18 X X 22 7.9 20 7.2
26 X X 1 0.4 1 0.4
31 X X 24 8.7 21 7.6
33 X X 21 7.6 16 5.8
35 X X 10 3.6 9 3.3
39 X X 8 2.9 7 2.5
40 X X 1 0.4 1 0.4
42 X 3 1.1 3 1.1
43 X0 0 0 0
44 X 1 0.4 0 0
45 X X 16 5.8 15 5.4
51 X X 19 6.9 13 4.7
52 X X 37 13.4 23 8.3
53 X X 3 1.1 2 0.7
54 X X 1 0.4 1 0.4
55 X0 0 0 0
56 X X 9 3.3 8 2.9
58 X X 15 5.4 14 5.1
59 X X 5 1.8 5 1.8
61 X0 0 0 0
62 X 1 0.4 1 0.4
64 X0 0 0 0
66 X X 9 3.3 5 1.8
67 X 1 0.4 1 0.4
68 X X 2 0.7 2 0.7
70 X X 2 0.7 2 0.7
71 XX 0 0 0 0
72 X0 0 0 0
73 X X 5 1.8 5 1.8
74 X 1 0.4 0 0
81 X0 0 0 0
82 X X 6 2.2 4 1.4
83 X 1 0.4 1 0.4
84 X 1 0.4 1 0.4
89 X 2 0.7 2 0.7
IS39 X 2 0.7 2 0.7
Any High Risk{ X X 258 93.1 255 92.1
Any HPV X X 265 95.7 265 95.7
*LiPA performed if LA was inadequate or if LA was negative for any type; positive result=positive by LA unless LA was inadequate or negative for any type, otherwise
positive result=positive by LiPA (N=277).
{Includes HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.
doi:10.1371/journal.pone.0034044.t002
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52.7% to 50.2%), HPV 33 (from 7.6% to 5.8%), and HPV 52
(from 13.4% to 8.3%). The median number of HR types per
woman (one) did not differ by testing algorithm. The mean
number of types per woman was slightly higher using the parallel
algorithm (1.31) than for the serial (1.14). Based on the similarity of
results using the parallel and serial algorithms, and the efficiency of
only performing two tests in a subset of samples in future
genotyping projects, we report the remainder of our results
according to the serial testing algorithm. Of the 278 valid results,
248 (89.2%) are from LA.
Of the 278 specimens with typing results, 32.7% (n=91) were
CIN2, 31.3% (n=89) were CIN3, and 30.9% (n=86) were SCC.
AIS comprised ,1% of specimens (n=2), and ADC accounted for
only 2.5% (n=7). The remaining 5 specimens were from subjects
who were diagnosed with cervical cancer other than SCC and
ADC (classified as ‘other invasive’), for a total of 98 (35.3%)
invasive lesions. Proportionally higher CIN2 lesions (14.3%) were
typed by LiPA than CIN3/AIS (12.4%) or invasive lesions (6.1%),
but the difference was not statistically significant (p=.17).
Among women with race information (n=204) in all diagnosis
grades, about half were non-Hispanic white, a third were non-
Hispanic black, and 10% were Hispanic. Median age increased
with increasing severity of squamous lesions, from 27 years in
CIN2 to 33 in CIN3 to 40 in ICC (p,.0001). Median age for AIS
was higher at 41 years and highest for ADC (48 years).
Type prevalence
Table 3 presents HPV DNA prevalence by diagnosis category.
No HPV DNA was detected in 11 specimens, 9 of which were
from invasive cancers. HR HPV was detected in 96.6% of CIN2,
95.5% of CIN3/AIS specimens and 85.7% of specimens with
invasive cancer (data not shown). HPV type 16 was the most
common in all diagnosis categories (except 7 ADC) and increased
from 45.6% in CIN2 to 52.8% in CIN3/AIS to 56.3% in SCC
specimens.
Table 3. HPV type prevalence among females diagnosed with CIN2+, North Carolina, 2001–2006.
CIN2
N=91
CIN3/AIS
N=89
SCC
N=86
ADC
N=7
Other Invasive
N=5
Total
N=278
n (%) n (%) n (%) n (%) n (%) n (%)
Negative 1 (1.1) 1 (1.1) 5 (5.7) 3 (42.9) 1 (20.0) 11 (4.0)
HR HPV
16 41 (45.6) 47 (52.8) 49 (56.3) 1 (14.3) 2 (40.0) 140 (50.4)
18 7 (7.8) 5 (5.7) 6 (6.9) 1 (14.3) 1 (20.0) 20 (7.2)
31 10 (11.1) 9 (10.3) 1 (1.1) – – – – 20 (7.2)
33 4 (4.4) 7 (8) 4 (4.6) 1 (14.3) – – 16 (5.8)
35 2 (2.2) 3 (3.4) 3 (3.4) – – 1 (20.0) 9 (3.2)
39 5 (5.6) 2 (2.3) – – – – – – 7 (2.5)
45 2 (2.2) 4 (4.6) 8 (9.2) 1 (14.3) – – 15 (5.4)
51 9 (10) 3 (3.4) 1 (1.1) – – – – 13 (4.7)
52 12 (13.3) 8 (9.2) 3 (3.4) – – – – 23 (8.3)
56 4 (4.4) – – 4 (4.6) – – – – 8 (2.9)
58 6 (6.7) 7 (8) 1 (1.1) – – – – 14 (5)
59 5 (5.6) – – – – – – – – 5 (1.8)
66 4 (4.4) – – 1 (1.1) – – – – 5 (1.8)
68 1 (1.1) 1 (1.1) – – – – – – 2 (0.7)
Possible HR
26 1 (1.1) – – – – – – – – 1 (0.4)
53 1 (1.1) 1 (1.1) – – – – – – 2 (0.7)
67 – – 1 (1.1) – – – – – – 1 (0.4)
69 – – – – 1 (1.1) – – – – 1 (0.4)
73 3 (3.3) – – 2 (2.3) – – – – 5 (1.8)
82 1 (1.1) – – 1 (1.1) – – – – 2 (0.7)
HPVX 2 (2.2) – – – – – – – – 2 (2.2)
IS39 – – 2 (2.3) – – – – – – 2 (0.7)
LR HPV
6 3 (3.3) – – – – – – – – 3 (1.1)
11 1 (1.1) – – – – – – – – 1 (0.4)
CIN2+: cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ (AIS).
Note. 2 AIS cases with single HPV 16 infection are combined with CIN3.
doi:10.1371/journal.pone.0034044.t003
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cancer specimens. As shown in Figure 1, HPV 45 was the second
most common type among invasive cases (9.2%), slightly more
than HPV 18 at 8.2%. Prevalence of other phylogenetically
related HPV types detected among invasive cases was 5.4% for
HPV 33, 4.1% for HPV 35, 3.1% for HPV 52 and 1.0% for HPV
58. LR HPV types 6, 11, 40, 42, 54, 83, 84, and 89 were detected
in approximately 10% of CIN2 lesions, mostly as a co-infection
Figure 1. Distribution of single and multiple high risk (HR) HPV types by diagnosis grade.
doi:10.1371/journal.pone.0034044.g001
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CIN3 (HPV 62) specimens (data not shown). No LR HPV types
were detected in SCC, ADC, or other invasive cervical specimens.
Overall, HPV 16 or 18 was detected in 56.5% of specimens.
The proportion of HPV 16/18-related lesions appeared to
increase with disease severity, although this trend was not
statistically significant (Table 4). We found no statistical difference
in the proportion of 16/18-related lesions by race or by age
category, overall or stratified by disease severity as shown in
Table 4.
Figure 1 displays HPV type distribution by single and multiple
type infection. Among SCC and ADC cases, 94.4% had only a
single HR HPV detected; single infections were less common in
CIN3 and AIS cases (86.4%) and lowest in CIN2 specimens
(65.6%) (p,.0001). Multiple type infection decreased with
increasing age group (58% in females ,30, 27.7% in females
aged 31–49, and 14.9% in females .=50 years; p,.0001).
Discussion
Prevalence and type distribution of HPV in cervical precancers
and invasive cancers is not well-described in the United States
[11]. Using archived FFPE biopsy tissue from a large source
population of females with histologically-confirmed precancerous
and invasive cervical lesions, we examined HPV type prevalence
and evaluated laboratory methods for HPV DNA detection in
FFPE biopsy tissue. Specifically, we used a combination of LA and
LiPA HPV genotyping assays to maximize HPV DNA detection in
archived biopsy specimens.
Several studies have reported high concordance between the LA
and LiPA assays for detecting HPV DNA in cervical cells
[10,12,13,14]. However, assay performance on cytology specimens
are not directly comparable to that for FFPE specimens given the
potential for DNA degradation in the latter. Fewer studies have
investigated the use of commercial assays for HPV genotyping in
FFPE specimens. In a study from Australia, Tan et al. compared
use of LA vs LiPA for HPV genotyping of a small sample of vulval
biopsy specimens, and concluded that LiPA has higher sensitivity
to detect DNA in archived biopsy tissue [15]. A larger study by
Wheeler et al. conducted in a U.S. population, however, found
high (.95%) crude agreement between the 2 assays for most HPV
DNA types in cervical FFPE tissue [6]. Consistent with the U.S.
study, our data indicate that using a serial testing algorithm
whereby only HPV-negative and inadequate samples by LA are
tested with LiPA results in very little change in prevalence
estimates of HR-HPV for most types compared to testing all
specimens with both tests in parallel. Using a serial algorithm, we
demonstrate greatly improved efficiency without compromise to
sensitivity in detection or bias in detection of HR HPV types. If
only LA negative or inadequate samples had been tested by LiPA,
238 tests could have been avoided.
As expected, HPV16 was the most commonly detected HPV
type in all diagnosis categories, followed by HPV 52, 18, 31, 33,
and 45. These findings are similar to that found in non-Hispanic
white and Hispanic women with CIN3/AIS and invasive cervical
cancer in the U.S. [6], as well as in other international settings
[11,16]. We found that HPV16 was more likely to occur as a single
infection in CIN3/AIS and invasive cancers compared to CIN2.
This could be due to differential clearance of HR HPV types, but
the results may be confounded by age which we were unable to
control for given the small sample size of the study [17,18,19].
HPV16 and 18 were less commonly detected in CIN2 and CIN3/
AIS than ICC lesions, and distribution of HR types differed by
lesion grade. Among invasive cases, HPV45 was the second most
common type (10%); HPV18 was third highest (8%) followed by
33 (6%). We found less HR HPV positivity in invasive cases
compared to lower grade lesions. The reasons for this are unclear
and could reflect differential specimen quality. However, the
proportion of invasive cases associated with HR HPV (85.7%,
95% CI: 78.8–92.6) is similar to that found in other studies. For
example, Wheeler et al. reported a 90.0% HPV positivity in U.S.
women with invasive cervical cancer compared to 97.1% HPV
positivity in those with CIN3 or AIS [6].
Our study has several limitations. First, our population was
restricted to adult female residents of North Carolina and may not
be generalizable to other U.S. populations. However, we obtained
Table 4. HPV 16 and 18 type prevalence in cervical intraepithelial lesions, by diagnosis and demographics.
Overall HPV 16/18-related
lesions
HPV 16/18-related CIN2
lesions
HPV 16/18-related CIN3/AIS
lesions
HPV 16/18-related
invasive lesions
Number of women% Number of women%
Number of
women %
Number of
women %
Overall 278 56.5 91 52.8 89 57.3 98 59.2
Race/ethnicity
NH white 94 57.5 26 46.2 34 61.8 33 63.6
NH black 71 54.9 26 53.9 23 47.8 22 63.6
Hispanic 25 40.0 9 33.3 10 40.0 6 50.0
Other 14 78.6 6 50.0 5 100.0 3 100.0
P 0.13 0.79 0.11 0.53
Age, years
,30 90 54.4 57 52.6 30 56.7 3 66.7
30–39 90 57.8 27 55.6 44 54.6 19 66.7
.=40 98 57.1 7 42.9 15 66.7 76 63.9
Ptrend 0.77 0.87 0.90 0.84
NH: non-Hispanic.
CIN: cervical intraepithelial neoplasia.
doi:10.1371/journal.pone.0034044.t004
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majority of residents of North Carolina to minimize selection bias.
Second, because the study was cross-sectional in nature, it was
neither possible to investigate the effects of aging on HPV
persistence or type distribution, nor to examine the influence of
HPV types on disease progression. Third, we had limited statistical
power to investigate HPV coinfection patterns by disease grade.
Fourth, we did not perform additional testing to validate typing
results discrepant between LA and LiPA. We assumed that results
positive by either method were correct, but some might actually be
falsely positive. Concordance between LA and LiPA may differ
depending on method of sample collection, extraction method, or
disease prevalence.
In summary, we used specimens available from a pilot study to
develop an efficient approach to HPV testing of archived FFPE
specimens. Currently, the serial algorithm is being applied to a
variety of other population-based studies of HPV type distribution
in cancer and precancer specimens (CDC, unpublished data) [6].
Our data also provide important information about the distribu-
tion of individual HPV types in cervical disease prior to HPV
vaccine introduction in North Carolina. The impact of HPV
vaccines in reducing the burden of cervical and other HPV-
associated cancers is of greatest concern, but it may take many
years to demonstrate population-level reductions in these diseases.
Cervical precancer lesions (CIN2/3) take less time to develop and
are the accepted proxy for monitoring the impact of vaccine on
cervical cancer. North Carolina has a large rural population at
higher risk of cervical cancer, and an annual cervical cancer
incidence of 8.2 cases/100,000 women [20,21]. Thus, these
baseline results may be a useful contribution to monitoring
primary and secondary cervical cancer prevention efforts in North
Carolina.
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